Oncotelic Therapeutics to Present at OTCQB Virtual Investor Conference, Highlighting Advances in Cancer Drug Development

Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a clinical-stage biotechnology company focused on developing innovative therapies for cancer and other serious diseases, has announced that its CEO and Chairman, Dr. Vuong Trieu, will present at the OTCQB Virtual Investor Conference on Aug. 6, 2026, at 2:30 p.m. ET. The presentation will include a live question-and-answer session, offering investors an opportunity to engage directly with the company's leadership. This event is significant as it provides a platform for Oncotelic to communicate its recent progress and strategic direction to the investment community.

The company plans to highlight several key developments, including the advancement of its Phase 1b intravenous Everolimus (Sapu003) trial to the next dose cohort. This progression is a critical milestone in the clinical development of the therapy, as it indicates that the current dose level has met safety and tolerability criteria, allowing for dose escalation. Additionally, Oncotelic has expanded its European clinical sites, which may enhance patient recruitment and diversify the trial's geographic footprint. These steps are essential for the eventual registration and commercialization of the drug candidate.

Another focal point of the presentation will be the validation of the company's Deciparticle™ platform through peer-reviewed publications. The Deciparticle technology is a proprietary drug delivery system designed to improve the pharmacokinetics and biodistribution of therapeutic agents, potentially increasing efficacy while reducing side effects. Peer-reviewed validation adds scientific credibility and may facilitate partnerships or licensing opportunities. The company also emphasizes its scalable cGMP manufacturing capabilities, which are crucial for producing clinical and commercial-grade materials, ensuring supply chain reliability.

Furthermore, Oncotelic continues to develop its AI-driven drug discovery, robotics, and nanomedicine platforms. These initiatives reflect a broader industry trend toward integrating artificial intelligence and automation to accelerate the identification and optimization of drug candidates. By leveraging these technologies, Oncotelic aims to reduce development timelines and costs, ultimately improving patient outcomes. The convergence of these advanced platforms positions the company at the forefront of precision medicine, with a focus on RNA therapeutics and nanomedicine delivery.

The implications of this presentation are multifaceted. For investors, it offers transparency into the company's operational milestones and future prospects. For the biotech sector, it underscores the growing importance of AI and novel delivery systems in oncology drug development. Oncotelic's progress in the Phase 1b trial, coupled with its platform validation and manufacturing readiness, suggests that the company is advancing toward key value inflection points. The live Q&A session will allow stakeholders to gain deeper insights into the company's strategy and execution, potentially influencing investment decisions.

For more information about the event and to access the presentation, interested parties can visit the official conference link at https://nnw.fm/fGHUt. Additionally, the latest news and updates regarding Oncotelic Therapeutics are available in the company's newsroom at https://nnw.fm/OTLC.